Business Overview: Schrödinger, Inc. (NASDAQ: SDGR)

---

Executive Summary

Schrödinger, Inc., founded in 1990 and headquartered in New York, operates a physics-based computational platform that combines physics methods with machine learning to predict molecular properties before synthesis, with the stated mission of "transforming the way therapeutics and materials are discovered." The company monetizes this platform through three interrelated lines of business: a software business licensed to pharmaceutical, biotech, and materials science customers; collaborative drug discovery partnerships with major pharmaceutical companies; and a proprietary drug discovery pipeline of its own clinical-stage therapeutic candidates.

Schrödinger generated $255.9 million in total revenue in 2025, with software revenue of $199.5 million (up 11%) and drug discovery revenue of $56.4 million, but posted a net loss of $103.3 million as it continues to invest in both platform development and its own proprietary pipeline. A major 2025 cash event was the $150 million upfront payment received in January 2025 under its November 2024 Novartis collaboration, which carries up to $2.272 billion in potential future milestones plus tiered royalties.

---

1. Core Business Model & How They Work

Schrödinger monetizes its physics/ML discovery platform three ways: direct software licensing, collaborative partnerships where pharma partners pay for platform access and milestones/royalties, and its own proprietary drug programs that it eventually plans to partner out.

[ Physics-Based Computational Platform ] ➡️ [ Software Licensing (SaaS) + Collaborative Drug Discovery (Milestones/Royalties) + Proprietary Pipeline ] ➡️ [ Revenue + Future Royalty/Licensing Optionality ]

Key Revenue Streams

1. Software revenue: $199.5 million in 2025 (up 11%), measured partly through Annual Contract Value (ACV) of $198.5 million (up 4%). The "Top 20 pharma" cohort alone represents $73.7 million (37%) of software revenue and $80.8 million (41%) of ACV, showing concentrated but deep penetration among the largest pharmaceutical companies.
2. Drug discovery revenue: $56.4 million in 2025, earned through 20 active collaborative programs with partners including Bristol Myers Squibb, Eli Lilly, Novartis, Otsuka, and Sanofi, 16 of which remain eligible for future royalties.
3. Upfront and milestone payments: The November 2024 Novartis collaboration alone delivered a $150 million upfront payment (received January 2025) against up to $2.272 billion in potential milestones plus tiered royalties — illustrating the scale of economics possible from a single major partnership.
4. Equity stakes in partner companies: Schrödinger holds equity positions in collaboration partners, including a 31.5% stake in Bright Angel Therapeutics and smaller stakes in Ajax Therapeutics and Structure Therapeutics, giving it additional upside exposure beyond direct revenue.
5. Proprietary pipeline optionality: Clinical programs like SGR-1505 (MALT1 inhibitor, Phase 1) and SGR-3515 (Wee1/Myt1 inhibitor, Phase 1) represent potential high-value assets, though the company has stated it plans to seek partners for clinical programs rather than fund trials independently going forward.

---

2. Business Segments

Schrödinger does not report formal geographic or product segments; it organizes disclosure by its three lines of business.

┌─────────────────────────────────────────┐
│             Schrödinger, Inc.                │
└────────────────────┬────────────────────┘
                      │
   ┌──────────────────┼──────────────────────┐
   ▼                   ▼                      ▼
┌─────────────┐  ┌─────────────────┐  ┌───────────────────┐
│ Software        │  │ Collaborative       │  │ Proprietary            │
│ Licensing         │  │ Drug Discovery       │  │ Drug Discovery          │
│ $199.5M (78%)      │  │ (20 active programs; │  │ (SGR-1505, SGR-3515,    │
│                    │  │  16 royalty-eligible) │  │  and other candidates)   │
└─────────────┘  └─────────────────┘  └───────────────────┘
         Drug discovery revenue combined: $56.4M (22%)

---

3. Product Portfolio

---

4. Competitive Landscape

Item 1 content available does not name specific competitors directly, but based on the described business, Schrödinger's competitive landscape includes computational drug discovery and molecular modeling software providers, in-house computational chemistry teams at large pharmaceutical companies, and other AI/ML-driven drug discovery platforms that have proliferated in recent years. The company's physics-based (rather than purely ML/AI-driven) approach, long academic adoption (used at more than 1,750 academic institutions), and deep "Top 20 pharma" penetration differentiate it from newer, less-established computational discovery entrants.

---

5. Strategic Strengths & Risks

Strengths

• Deep pharma penetration with high retention: 96% gross dollar retention among commercial customers, with the Top 20 pharma cohort contributing a disproportionate 41% of ACV, shows the platform is deeply embedded in the discovery workflows of the industry's most sophisticated and well-funded players.
• Validated, differentiated physics-based technology: Unlike purely ML-driven competitors, Schrödinger's physics-based approach provides a distinct scientific foundation that has been validated through decades of academic and commercial use.
• Major collaboration economics: The Novartis deal alone (up to $2.272 billion in potential milestones) illustrates the scale of value the platform can unlock through partnership, well beyond direct software licensing revenue.
• Diversification beyond pharma: Materials science applications (OLED, aerospace, semiconductors, batteries) provide a growth avenue less tied to pharmaceutical R&D budget cycles.
• Equity upside in partner companies: Stakes in Bright Angel Therapeutics (31.5%) and others provide additional option value if those partner companies succeed.

Risks

• Continued net losses: A $103.3 million net loss in 2025 shows the company remains unprofitable as it invests in platform development and its own pipeline, requiring continued access to capital or faster revenue growth to reach sustainable profitability.
• Declining net dollar retention: Net dollar retention fell to 100% from 113%, and the number of commercial customers with ACV of at least $1.0 million fell to 27 from 29 — early signals of potential deceleration in software business expansion, even as average ACV per large customer grew.
• Clinical pipeline risk: SGR-2921 was discontinued in August 2025 after two patient deaths in an AML trial — a stark reminder of the inherent risk in drug development, even for a company built on predictive discovery technology.
• Revenue concentration in a small number of large deals: Collaboration revenue is lumpy and dependent on a relatively small number of large pharma partnerships (e.g., the single Novartis deal's outsized economic impact), creating potential revenue volatility.
• Strategic shift away from independently funding clinical trials: The company's stated plan to seek partners for clinical programs rather than fund trials independently reduces capital risk but also caps Schrödinger's ability to capture the full value of drug discovery success on its own.

---

6. Financial Overview

---

7. Summary Conclusion

Schrödinger's moat is built on a scientifically differentiated, physics-based discovery platform that has achieved deep penetration among the world's largest pharmaceutical companies and broad academic adoption, giving it real switching-cost advantages once customers embed the platform (particularly LiveDesign) into their discovery workflows. The business model's three-pronged structure — software, collaborative drug discovery, and proprietary pipeline — provides multiple paths to value creation, exemplified by the Novartis deal's outsized potential economics, but the company remains unprofitable and showed some signs of decelerating customer expansion in 2025 (declining net dollar retention, fewer large commercial customers). The central question for Schrödinger is whether software ACV growth can reaccelerate and whether its collaboration and proprietary pipeline bets — inherently binary, as the SGR-2921 discontinuation illustrates — will generate enough milestone and royalty revenue to justify years of continued investment losses.

Sources: Schrödinger, Inc. 10-K FY2025, SEC EDGAR